GenoMed's Fourth Horse Recovering from Presumed West Nile Virus Encephalitis.
A week ago, a horse owner in Seguin, Texas telephoned GenoMed to say that her horse, named Seminole Wind, was dying. Despite West Nile virus serum, steroids, and Benamine, the horse could no longer stand, or even blink when its eye was touched.
Within 2 hours of the first dose of GenoMed's treatment, the horse got to his feet and began drinking and eating, but went down again 24 hours later. Since then, he's been slowly getting stronger. Recently, he began staying on his feet longer.
West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "After an initial response to our treatment, this horse relapsed. We saw this with our previous horse, whose treatment was stopped. But this horse's owner persevered. Seminole Wind seemed to get slightly better after each dose, only to fall back. He slept a lot. This is our first horse to recover after being so sick. Normally, going down means death within a couple of days."
Added Dr. Moskowitz, "This past week has been very tough for the owner, who has shown incredible persistence and TLC for her horse. A stronger medication may work better next time."
Dr. Moskowitz concluded, "Seminole Wind showed that our approach to West Nile virus is worth pursuing. Most exciting is that our approach could work for most viruses, including avian influenza or bird flu. With each clinical case, we learn more."
Early treatment of WNV encephalitis in humans has yielded the best results, so public awareness of GenoMed's treatment is important. A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.
The protocol for West Nile virus is available for free from GenoMed's website, www.genomed.com, as is GenoMed's protocol for avian influenza ("bird flu"). Horse owners are encouraged to contact Dr. Moskowitz directly (see contact information above) to discuss drugs and dosing.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 21, 2006|
|Previous Article:||Marie Osmond Shares a Smile and a DQ(R) Blizzard(R) to Support Children's Miracle Network.|
|Next Article:||Castelle Announces Integration of Its Network Fax Servers with Equitrac Cost Recovery and Print Management Solutions.|